The Medical and Surgical Practice of NaProTECHNOLOGY, 407-412, 2004

Chapter 33: Osteoporosis and Role of CrMS

Thomas W Hilgers

Author affiliations
  • Pope Paul VI Institute for the Study of Human Reproduction, Omaha, Nebraska. ROR
Read at source

Abstract

Chronic anovulation and progesterone or estradiol deficiency identified through CrMS charting represent periods of suboptimal bone accrual in women of reproductive age, because both estradiol and progesterone contribute to skeletal maintenance -- estradiol through suppression of osteoclast activity and progesterone through osteoblast stimulation. NaProTECHNOLOGY uses longitudinal CrMS records of ovulatory status and hormone profiles as a bone-health risk screen, guiding cycle-synchronized bioidentical hormone replacement to restore normal estrogen-progesterone balance and potentially mitigate progression toward osteoporosis in women with chronic cycle-based endocrine deficiencies.

Topics

low bone density in young women with irregular periods, can birth control pills cause osteoporosis, progesterone for bone health, mucus pattern and bone density connection, creighton model fertility charting predicts bone loss, premenopausal osteoporosis risk factors, luteal phase estrogen deficiency bone density, depo provera bone mineral density loss, peak plus 7 hormone testing bone health, oral contraceptive bone mineral density premenopausal, type iv luteal phase defect osteoporosis, menstrual cycle score low bone mass, mucus cycle score bone density correlation, post-peak estradiol sum bone mineral density, androstenedione dheas bone density relationship, triestrogen progesterone postmenopausal bone density, bioidentical hormone replacement osteoporosis treatment, dxa scan spine hip t-score interpretation, reproductive age women osteopenia screening, cervical mucus quality predicts bone loss, early menopause bilateral oophorectomy fracture risk, premenopausal amenorrhea bone mineral density, postovulatory progesterone normal but low estradiol bone health, hormonal contraception long term bone effects, naprotechnology approach osteoporosis prevention, targeted luteal phase hormone evaluation bone density, isomolecular hormone replacement therapy bone formation, peak plus 7 androstenedione bone mineral density

Cite this article

Hilgers, T. W. (2004). Chapter 33: Osteoporosis and Role of CrMS. *The Medical and Surgical Practice of NaProTECHNOLOGY*, 407-412.

Related articles